Evidence map›Paper›PMID 33980831›Full record

Trial reportBlood cancer journal2021

A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab.

Joseph Mikhael, Karim Belhadj-Merzoug, Cyrille Hulin, Laure Vincent, Philippe Moreau, Cristina Gasparetto, Ludek Pour, Ivan Spicka, Ravi Vij, Jeffrey Zonder and 11 more

Open access · goldAbstract readClinical Trial, Phase IILetter
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood cancer journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 2 pooled it
10.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 2 syntheses or guidelines pooled it, 88 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. An Update of the Appropriate Sequencing for Salvage Therapies in Multiple Myeloma.Mediterranean journal of hematology and infectious diseases · 2025
    Review
  15. Observational
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 19 institutions in 5 countries.

Joseph MikhaelTranslational Genomics Research Institute, City of Hope Cancer Center, Phoenix, AZ, USA.
Karim Belhadj-MerzougUnité Hémopathies Lymphoïdes, CHU Henri Mondor, Créteil, France.
Cyrille HulinService d'hématologie, CHRU Hôpitaux de Brabois, Nancy, France.
Laure VincentDépartement d'hématologie Clinique, Centre Hospitalier Universitaire de Montpellier, Montpellier, France.ORCID 0000-0001-5904-1286
Philippe MoreauHematology Department, Nantes University Hospital, Nantes, France.
Cristina GasparettoDuke Cancer Institute, Duke University, Durham, NC, USA.
Ludek PourDepartment of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic.
Ivan Spicka1st Department of Medicine-Department of Hematology First Faculty of Medicine Charles University and General Hospital in Prague, Prague, Czech Republic.
Ravi VijDivision of Medical Oncology, Washington University, St Louis, MO, USA.
Jeffrey ZonderDepartment of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.
Djordje AtanackovicDepartment of Medicine, Bone Marrow Transplant, University of Maryland Greenebaum Cancer Center, Baltimore, MD, USA.
Nashat GabrailGabrail Cancer Center, Canton, OH, USA.
Thomas G MartinHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
Aurore PerrotCHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d'hématologie, Toulouse, France.ORCID 0000-0003-0131-8689
Samira BensfiaSanofi Global Oncology, Cambridge, MA, USA.
Qilong WengSanofi Clinical Sciences and Operations, Beijing, China.
Claire BrillacSanofi Translational Medicine and Early Development, Paris, France.ORCID 0000-0002-1743-3211
Dorothée SemiondSanofi Translational Medicine and Early Development, Paris, France.
Sandrine MacéSanofi Translational Medicine and Early Development, Paris, France.
Kathryn P CorzoSanofi Global Oncology, Cambridge, MA, USA.
Xavier LeleuTakeda Pharmaceuticals, Cambridge, MA, USA. Xavier.LELEU@chu-poitiers.fr.ORCID 0000-0002-9822-4170
Sanofi (France) · FRAVEO Oncology (United States) · USCentre Hospitalier Régional et Universitaire de Nancy · FRCentre Hospitalier Universitaire de Montpellier · FRCentre Hospitalier Universitaire Henri-Mondor · FRCharles University · CZDuke University · USGabrail Cancer Center · USInserm · FRNantes Université · FRSanofi (China) · CNTakeda (United States) · USTranslational Genomics Research Institute · USUniversité Toulouse III - Paul Sabatier · FRUniversity Hospital Brno · CZUniversity of California, San Francisco · USUniversity of Maryland, Baltimore · USWashington University in St. Louis · USWayne State University · US

Funding

Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI DONNA NIEDZWIECKI · 1985 to 2026
$174.8M
NCI NIH HHS P30 CA014236
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalDrug Resistance, NeoplasmFemaleHumansMaleMiddle AgedMultiple MyelomaTreatment OutcomeAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunologicaldaratumumabisatuximab

Identifiers

PMID33980831
PMCPMC8116334
OpenAlexW3160854760

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.